Two tests and one reference [General Sta­tis­tics]

posted by Brus – Spain, 2020-08-31 09:58 (288 d 22:59 ago) – Posting: # 21895
Views: 3,839

Dear Helmut and all,

If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?

In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).

If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?

Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?

Best regards,

Complete thread:

Activity
 Admin contact
21,522 posts in 4,499 threads, 1,523 registered users;
online 17 (1 registered, 16 guests [including 3 identified bots]).
Forum time: Wednesday 08:57 CEST (Europe/Vienna)

Don’t undertake a project
unless it’s manifestly important
and nearly impossible.    Edwin H. Land

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5